Biogen Settles Suit Over Alleged Alzheimer’s Antibody Copycat

Biogen Inc. settled its claims against Creative Biolabs Inc. for selling a copycat version of Biogen’s aducanumab antibodies, which are being investigated as a possible treatment for Alzheimer’s disease.

Creative Biolabs will stop making, selling, importing, or exporting aducanumab and using related trademarks under the settlement agreement, according to a Wednesday filing in Massachusetts federal court.

Biogen specializes in treating neurological diseases. It licensed aducanumab from Swiss biopharmaceutical company Neurimmune Therapeutics AG to collaborate on developing the antibody to treat Alzheimer’s.

Biogen’s complaint accused CB of “brazenly copying” the patented antibodies to sell on its website. It also said CB’s ...